Research Topics
| Petr HusaSummaryAffiliation: Masaryk University Country: Czech Republic Publications
| Collaborators
|
Detail Information
Publications
Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patientsP Husa
Department of Infectious Diseases, University Hospital, Brno, Czech Republic
Acta Virol 45:7-11. 2001....- [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics]Petr Husa
Department of Infectious Diseases, Medical Faculty, Masaryk University and Faculty Hospital Brno, Czech Republic
Klin Mikrobiol Infekc Lek 14:67-73. 2008.... - [Hepatitis C virus infection in sex workers]Petr Husa
Department Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
Klin Mikrobiol Infekc Lek 13:66-9. 2007..The work assessed the prevalence of hepatitis C virus (HCV) infection in a representative sample of both male and female sex workers with the aim of assessing sexual transmission of HCV infection... - [The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy]P Husa
Klinika infekcních chorob Lékaské fakulty MU a FN Brno
Vnitr Lek 52:590-5. 2006..Today, the standard therapy of patients with chronic HCV (hepatitis C virus) infection is based on combination of pegylated interferon alpha (PEG-IFN) and ribavirin... - [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C]P Husa
Klinika infekcních chorob Lékarské fakulty MU a FN Brno
Vnitr Lek 52:153-9. 2006..Pegylated interferon alpha (PEG-IFN) and ribavirin combination therapy is the contemporary standard therapy of the patients chronically infected with hepatitis C virus (HCV)... - Hepatitis DP Husa
Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
Acta Virol 49:219-25. 2005..The results of antiviral therapy of hepatitis D patients are not satisfactory. Alpha-interferon (alpha-IFN) in high doses (9-10 MU three times a week for 12 months) is usually recommended... - Efficacy and safety of chronic hepatitis C treatment in hemophilic patientsP Husa
Department of Infectious Diseases, University Hospital Brno, Czech Republic
Hepatogastroenterology 52:1541-4. 2005..Chronic hepatitis C infection is very common among hemophiliacs in the developed World... - Treatment of chronic hepatitis C in hemophilic patientsP Husa
Department of Infectious Diseases, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
Acta Virol 48:35-8. 2004..We conclude that the efficacy and tolerability of the treatment of chronic hepatitis C in hemophiliacs did not differ from that of chronic hepatitis C in other patients... - Treatment of chronic hepatitis B in 2002P Husa
Department of Infectious Diseases, University Hospital, Masaryk University, Brno, Czech Republic
Bratisl Lek Listy 104:59-63. 2003..These approaches are including antisense oligonucleotides, ribozymes, inhibitors blocking virus entry into hepatocytes, and decoy virus or dominant negative mutants... - Efficacy of alpha-interferon therapy of chronic hepatitis patients infected with wild type hepatitis B virus and HBEAG-minus mutantP Husa
Department of Infectious Diseases, University Hospital Brno, Czech Republic
Acta Virol 45:293-7. 2001..Nevertheless, 4 of 7 patients of group B were negative for HBV DNA 12 months after the treatment and HBV DNA was eliminated during the treatment in all patients of group C; however, 3 patients relapsed after the treatment... - Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferonsP Husa
Department of Infectious Diseases, Teaching Hospital, Jihlavska 20, CZ 639 00 Brno, Czech Republic
Bratisl Lek Listy 102:248-52. 2001..We can expect the development more potent antiviral drugs or immune modulators for patients, which are primary resistant to alpha-interferon. (Tab. 3, Ref. 31).. 
Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern EuropePetr Husa
Department of Infectious Diseases, Faculty Hospital and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic
Eur J Gastroenterol Hepatol 23:375-81. 2011..To assess the safety and efficacy of 48 weeks of re-treatment with peginterferon α-2a (40 kD) plus ribavirin in previously treated hepatitis C virus (HCV) genotype 1 patients...- [Marseille fever imported from Spain]Michaela Freibergerová
Department of Infectious Diseases, University Hospital, Masaryk Universita, Brno, Czech Republic
Klin Mikrobiol Infekc Lek 10:191-4. 2004..The clinical manifestation, diagnosis and treatment of Marseille fever are discussed in greater detail... - Dual hepatitis B virus and hepatitis C virus infection: To treat or not to treat, and how?Petr Husa
J Gastroenterol Hepatol 20:669-70. 2005 - A double-blind placebo-controlled study of emtricitabine in chronic hepatitis BSeng Gee Lim
National University Hospital, Singapore
Arch Intern Med 166:49-56. 2006..CONCLUSION: In patients with chronic HBV, both positive and negative for HBe antigen, 48 weeks of emtricitabine treatment resulted in significant histologic, virologic, and biochemical improvement... - Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersEugene R Schiff
Division of Hepatology, University of Miami, Jackson Medical Towers, 1500 N W 12th Avenue, Suite 1101, Miami, FL 33136, USA
J Hepatol 38:818-26. 2003..We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously...